Here, we present our anesthetic management of a 6-year-old girl with previous history of malignant hyperthermia experience for the ventriculoatrial shunting.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Malignant hyperthermia is an uncommon life-threatening genetic sensitivity of skeletal muscles to volatile anesthetics and depolarizing neuromuscular relaxants triggered by anesthesia and is followed by an increase in temperature that may be fatal without prompt treatment.
📊
Key Findings & Data:Malignant hyperthermia is an uncommon life-threatening genetic sensitivity of skeletal muscles to volatile anesthetics and depolarizing neuromuscular relaxants triggered by anesthesia and is followed by an increase in temperature that may be fatal without prompt treatment.
💡
Conclusion & Impact:Here, we present our anesthetic management of a 6-year-old girl with previous history of malignant hyperthermia experience for the ventriculoatrial shunting.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Malignant hyperthermia is an uncommon life-threatening genetic sensitivity of skeletal muscles to volatile anesthetics and depolarizing neuromuscular relaxants triggered by anesthesia and is followed by an increase in temperature that may be fatal without prompt treatment. Here, we present our anesthetic management of a 6-year-old girl with previous history of malignant hyperthermia experience for the ventriculoatrial shunting.
Özet
Malign hipertermi, çizgili kasların volatil anestezikler ve depolarizan kas gevşetici ajanlarla karşılaştıklarında tetiklenen, yaşamsal tehlike arz eden, ender görülen bir genetik duyarlılık durumudur. Vücut sıcaklığında yükselme ile bulgu vermeye başlar ve acil tedavi edilmezse ölüme neden olur. Bu olgu sunumunda, malign hipertermi öyküsü olan ve ventriküloatriyal şant takılması nedeniyle genel anestezi uygulanacak olan 6 yaşındaki bir kız çocuğunda anestezi yönetimimiz anlatılmaktadır.
🔖
Cite This Article
KONYA, D., TURAL, S., GERÇEK, A., ÖZEK, M. M. (2022). Anesthetic management of a child with previous history of malignant hyperthermia: Case report. Türk Anestezi ve Reanimasyon Dergisi, Cilt: 36 - Sayı: 4, 250–252. https://ajindex.com/articles/619997
Jurkat-Rott K, McCarthy T, Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 2000; 23:4-17
Claxton BA, Cross MH, Hopkins PM. No response to trigger agents in a malignant hyperthermia-susceptible patient. Br J Anaesth 2002; 88:870-3
Girard T, Treves S, Censier K, et al. Phenotyping malignant hyperthermia susceptibility by measuring halothane-induced changes in myoplasmic calcium concentration in cultured human skeletal muscle cells. Br J Anaesth 2002; 89:571-9
Ali SZ, Taguchi A, Rosenberg H. Malignant hyperthermia. Best Pract Res Clin Anaesthesiol 2003; 17:519-33
Migita T, Mukaida K, Kawamoto M, et al. Propofol-induced changes in myoplasmic calcium concentrations in cultured human skeletal muscles from RYR1 mutation carriers. Anaesth Intensive Care. 2007; 35:894-8
Ording H, Brancadoro V, Cozzolino S, et al. In vitro contracture test for diagnosis of malignant hyperthermia the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol Scand 1997; 41:955-66
Fruen BR, Mickelson JR, Roghair TJ, et al. Effects of Propofol on Calcium sup. 2+ Regulation by Malignant Hyperthermia-susceptible Muscle Membranes. Anesthesiology 1995; 82:1274-82
Fratea S, Langeron O, Lecarpentier Y, et al. In vitro effects of dantrolene at rat myocardium. Anesthesiology 1997; 86:205-15.